Progyny Inc. (PGNY)
NASDAQ: PGNYHealth CareMisc Health and Biotechnology ServicesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PGNY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.63B
- P/E (TTM)
- 32.76
- Forward P/E
- 14.87
- EPS (TTM)
- $1.09
- Dividend yield
- None
- 52-week range
- 16.10 – 37.21
- Day range
- 35.50 – 36.07
- Volume / Avg
- 1.11M / 1.10M
- Beta
- —
- Shares outstanding
- 73.65M
52-week range
PGNY stock today
Progyny (PGNY) closed at $35.71 on Nov 20, up 0.73% (+$0.26), versus the S&P 500's 3.70% decline. At this level, PGNY sits near the top of its 52-week range of $16.10 to $37.21: 4.0% below the high, set on Nov 16, 2026 and 121.8% above the low. PGNY is up 39.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 38.1%.
At 32.8x trailing earnings, Progyny trades above the peer-group median of 22.4x. Its forward P/E of 14.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Progyny
Company profileProgyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions.
- Sector
- Health Care
- Industry
- Misc Health and Biotechnology Services
- CEO
- Mr. Peter Anevski CPA
- Headquarters
- New York, NY
- Employees
- 835
- IPO year
- 2019
- Website
- progyny.com
Financial highlights
Full financialsIn fiscal 2025, Progyny generated $1.29 billion in revenue, up 10.4% from fiscal 2024, its 8th consecutive year of revenue growth. Net income was $58.5 million (+7.7% year over year), for a net margin of 4.5% versus a median of 5.7% in the prior 5 years. Gross margin was 23.6% (up from 21.7%) and operating margin 6.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.29B | $1.17B | $1.09B | $786.91M | $500.62M |
| Growth | +10.40% | +7.22% | +38.34% | +57.19% | +45.17% |
| Net income | $58.52M | $54.34M | $62.04M | $30.36M | $65.77M |
| EPS (diluted) | $0.65 | $0.57 | $0.62 | $0.30 | $0.66 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$37.75+5.71%
- Strong buy 1
- Buy 9
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.15 vs $0.27
- Surprise
- -44.44%
PGNY news
All PGNY news- 5 Relative Price Strength Stocks to Tap Amid S&P 500 WeaknessNasdaqCOP, NUE, TDC, WWW
- Progyny: 3 Key Takeaways for Long-Term InvestorsNasdaqPGNY, BIO.B
- Fertility Treatment Leader Progyny Breaks Out Past Buy Point As Earnings Surge 113%Investor's Business Daily
- Progyny Reaches Analyst Target PriceNasdaqPGNY, HEI.A
- Progyny (PGNY) Q3 2026 Earnings Call TranscriptNasdaq
- Progyny raises 2026 revenue outlook to $1.365B-$1.385B as it adds 1.3 million new covered livesSeeking Alpha
- Progyny, Inc. Announces Third Quarter 2026 ResultsGlobeNewswire
- New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to BenefitsGlobeNewswire
Progyny peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AGLagilon health inc. | 90.24 | +0.83% | $1.52B | vs PGNY |
| SHCSotera Health Company | 15.91 | -1.85% | $4.54B | vs PGNY |
| VMDViemed Healthcare Inc. | 8.52 | -1.05% | $322.85M | vs PGNY |
| PARKPark Dental Partners Inc. | 17.03 | -6.79% | $94.26M | vs PGNY |
| CCELCryo-Cell International Inc. | 4.15 | 0.00% | $33.46M | vs PGNY |
| MGRXMangoceuticals Inc. | 0.1236 | -7.55% | $2.75M | vs PGNY |
| NIVFNewGenIvf Group Limited Class A | 0.0269 | -23.14% | $80.77K | vs PGNY |
| DVADaVita Inc. | 161.03 | +3.00% | $10.13B | vs PGNY |
Indexes, lists and sector
Progyny stock FAQ
What is Progyny's stock price today?
PGNY last traded at $35.71 as of Nov 20, 4:00 PM EST, up 0.73% on the day. Prices are delayed at least 15 minutes.
What is PGNY's P/E ratio?
PGNY trades at a trailing P/E ratio of 32.76 and a forward P/E of 14.87, compared with a median of 22.4 for its closest peers.
Who is Progyny's CEO?
Mr. Peter Anevski CPA is the chief executive officer of Progyny Inc., which has about 835 employees.
What is the PGNY 52-week high?
The 52-week high for PGNY is $37.21 and the 52-week low is $16.10. The stock is currently 4.0% below its high.